
Opinion|Videos|May 16, 2024
Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics
The expert panel explores the importance of communication and collaboration among care providers when patients with multiple myeloma who are receiving treatment with bispecific antibodies navigate transitions of care to and from various healthcare settings.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Trump Executive Order Recommends Separating MMR Into 3 Shots
2
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
3
Suzetrigine-Based Multimodal Therapy Enables Opioid-Free Recovery in Patients Receiving Surgery
4
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
5







































































































